BioPharma Dive July 30, 2024
The CEO noted how Pfizer’s danuglipron could still be the second oral GLP-1 treatment to enter registrational tests after Lilly’s orforglipron.
Pfizer missed its first chance at following Novo Nordisk and Eli Lilly into the fast-growing market for GLP-1 obesity drugs. CEO Albert Bourla is advising investors not to count it out too quickly the second time.
On Tuesday, as the company reported second quarter earnings, Bourla told analysts on a conference call he thinks Pfizer is still in good position to deliver an oral GLP-1 weight loss drug — the goal of many would-be rivals to Novo and Lilly.
The company’s recent advancement of its experimental pill, called danuglipron, came after several setbacks, including Pfizer’s decision to scrap another...
Today's Sponsors
Today's Sponsor